secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2025-12-23T23:59:59+00:00
Accession:  0001437749-25-038602
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 5.03, 5.07, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA requires second Phase 3 trial for Reviva's brilaroxazine in schizophrenia; NDA delayed to late 2027
--------------------------------------------------------------------------------

- FDA recommends RECOVER-2 Phase 3 trial (30/50 mg) before NDA submission; similar to RECOVER design.
- RECOVER-2 initiation planned H1 2026, data Q2 2027; NDA target Q4 2027, potential approval Q4 2028; est. cost ~$60M.
- Stockholders approved authorized share increase from 315M to 515M and reverse stock split (1:2 to 1:20, Board discretion).
- Warrant exercises Oct–Dec 2025: 19.8M shares, ~$6.7M net; cash ~$14.7M as of Dec 16, sufficient through Q2 2026 ex-RECOVER-2.
- Long-term safety data from RECOVER open-label extension over 52 weeks shows favorable tolerability and adherence.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774925038602/0001437749-25-038602-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774925038602/rvph20251216_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-038602

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer